FDA to outline antibiotic strategy

1 big problem: The current system doesn't give pharma companies an incentive to make new antibiotics. The point is to use them sparingly enough that pathogens don't become resistant, but a drug companies’ profits depend on heavier use.

• Gottlieb is expected to discuss the need for new payment models that better promote the development of new antibiotics. These models might pay more for drug upfront, but result in savings to the system down the road.
• For example, hospitals could pay a subscription fee for access to doses of new antibiotics, which would have to be high enough to make drug companies' investment worthwhile.